Major collaboration between CÚRAM and Boston Scientific announced by Taoiseach in Washington

A major research project between CÚRAM, the SFI Research Centre for Medical Devices based at National University Ireland (NUI ) Galway, and Boston Scientific, that will enhance medical devices that allow surgeons to support minimally invasive procedures when carrying out life-saving repairs for aneurysms and aortic valve repair, was announced by Taoiseach Leo Varadkar in Washington last evening.

Speaking at a Science Foundation Ireland (SFI ) event in Washington DC to celebrate and build scientific collaboration between Ireland and the United States as part of the St Patrick’s Day Festival, Mr Varadkar said that these new research projects are further evidence of the high calibre of our research talent and the continued growth of the medical devices sector in Ireland.

Boston Scientific products touch the lives of more than 25 million patients each year. Its Galway facility, which focuses on cardiovascular devices, is the company’s largest facility in Ireland. Key product lines include drug-eluting stents, biliary stents, and catheters.

This new project, led by CÚRAM principal investigator Dr Niamh Hynes, offers the exciting potential to develop new devices by bringing together clinical and industry expertise and experience with biomedical and scientific research excellence.

“This unique, multi-disciplinary, specialist environment is key to CÚRAM’s success in developing strong programmes of work with our industry partners; in this case bringing substantial investment from Boston Scientific,” said Prof Abhay Pandit, scientific director of the SFI Research Centre CÚRAM. “This project is in addition to three other ongoing research projects with Boston Scientific.”

Interventional cardiology is a branch of cardiology dealing specifically with catheter-based treatment of structural heart diseases. Minimally invasive transcatheter procedures for aortic valve repair, which involve inserting a replacement valve are being used more frequently, reducing the risk of surgery for patients.

Research is now focusing on the development of novel interventional solutions, which allow blood to flow in the correct direction through the heart. CÚRAM principal investigator, Dr Faisal Sharif, in collaboration with Boston Scientific, is developing technology to further reduce risk and improve outcomes for patients undergoing these surgeries.

Another research project, led by CÚRAM investigator Prof Tim O’Brien, is carrying out a preclinical evaluation of a catheter device to support muscle and vascular regeneration in patients suffering from critical limb ischaemia; a severe obstruction of the arteries which reduces blood flow to the extremities. CÚRAM investigators Prof Gearoid Ó Laighin and Dr Leo Quinlan are also collaborating with Boston Scientific on the development of a novel implantable electrical stimulation device to improve cardiovascular circulation.

Prof Mark Ferguson, Science Foundation Ireland Director General and chief scientific adviser to the Government of Ireland, said that the significant work being carried out by the SFI Research Centre CÚRAM continues to position Ireland at the forefront of the world medical device industry. I am delighted with the announcement of this new research partnership, which highlights the world-class reputation of Ireland as an important centre for R&D.

“The deepening of CÚRAM’s industry research collaborations is a testament to the research talent and collaborative environment which companies can access in Ireland. I am also confident that the project outcomes have the potential to positively transform human health across the world,” he said.

“CÚRAM’s goal is to establish long-term strategic relationships with our industry partners, to complete projects that advance medical device technologies and inventions and convert these into products and services that benefit the patient,” said Prof Pandit.

“Our industry programme team facilitates and supports collaborations such as the projects we are working on with Boston Scientific; from the initial enquiry right through to knowledge transfer and the identification of future projects.”

Advertisement

 

Page generated in 0.1997 seconds.